Skip to main content
SpringerLink
Log in

Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using68Ga-DOTATOC PET and comparison with18F-FDG PET

  • Original article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Dynamic PET studies with68Ga-DOTATOC were performed in patients with non-small cell lung cancer (NSCLC) to assess the somatostatin receptor 2 (SSTR2) expression. Furthermore, dynamic18F-fluorodeoxyglucose (FDG) studies were performed in the same patients to compare the SSTR2 expression with the tumour viability.

Methods

The study population comprised nine patients, examined with both tracers on two different days within 1 week. Standardised uptake values (SUVs) were calculated and a two-tissue compartment model was applied to the data. Furthermore, a non-compartment model based on the fractal dimension (FD) was applied to the data.

Results

The DOTATOC uptake was generally lower than the FDG uptake. Moderately enhanced DOTATOC uptake was noted in seven of the nine tumours. All kinetic parameters exceptk 4 were lower for DOTATOC than for FDG. The mean SUV was 2.018 for DOTATOC, in comparison to 5.683 for FDG. In particular,k 3 was highly variable for DOTATOC and showed an overlap with the normal lung tissue. The fractional blood volumeV B was relatively low for both tracers, not exceeding 0.3. The highest significant logarithmic correlation was found for the FD of the two tracers (r=0.764,p=0.017). The logarithmic correlation for SUVs was also significant (r=0.646,p=0.060), as was that forV B (r=0.629,p=0.069). In contrast, none of the eight metastases which were positive on FDG PET showed any DOTATOC uptake.

Conclusion

The results demonstrated moderate68Ga-DOTATOC uptake in primary NSCLC but did not provide any evidence for SSTR2 expression in metastases. This may be caused by loss of the gene expression in metastases as compared with the primary tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Mena E, Camacho V, Estorch M, Fuertes J, Flotats A, Carrió I.99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1399–1404

    Article  PubMed  Google Scholar 

  2. Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, et al. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Int J Oncol 2003;22:1141–1146

    PubMed  CAS  Google Scholar 

  3. Bohuslavizki KH, Brenner W, Braunsdorf WE, Behnke A, Tinnemeyer S, Hugo HH, et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun 1996;17:302–310

    Article  PubMed  CAS  Google Scholar 

  4. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;7:1974–1981

    Article  Google Scholar 

  5. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–648

    PubMed  CAS  Google Scholar 

  6. Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med 1997;38:1818–1823

    PubMed  CAS  Google Scholar 

  7. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A Java environment for medical image data analysis: initial application for brain PET quantitation. Med Inform 1998;23:207–214

    CAS  Google Scholar 

  8. Miyazawa H, Osmont A, Petit-Taboue MC, Tillet I, Travere JM, Young AR, et al. Determination of18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods 1993;50:263–272

    Article  PubMed  CAS  Google Scholar 

  9. Sokoloff L, Smith CB. Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Widén L, editors. The metabolism of the human brain studied with positron emission tomography. New York: Raven Press; 1983; p.123–148

    Google Scholar 

  10. Ohtake T, Kosaka N, Watanabe T, Yokoyama I, Moritan T, Masuo M, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med 1991;32:1432–1438

    PubMed  CAS  Google Scholar 

  11. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Mikolajczyk K, Lehnert T, Bernd L, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med 2003;2:306–313

    Google Scholar 

  12. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of (18F)-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004;125:1413–1423

    Article  PubMed  Google Scholar 

  13. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology 1999;213:530–536

    PubMed  CAS  Google Scholar 

  14. Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR 1 and SSTR 2, in human lung cancer cell lines. Life Sci 1994;55:1797–1806

    Article  PubMed  CAS  Google Scholar 

  15. Blum J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with a somatostatin analog99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232–1238

    Article  PubMed  CAS  Google Scholar 

  16. Kahn D, Menda Y, Kernstine K, Bushnell D, McLaughlin K, Miller S, et al The utility of99mTc depreotide compared with F-18-fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;125:494–501

    Article  PubMed  CAS  Google Scholar 

  17. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide (DOTA-TOC) kinetics in patients with meningiomas. J Nucl Med 2005;46:763–769

    PubMed  CAS  Google Scholar 

  18. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Pharmacokinetic studies of 68Ga-DOTATOC PET in patients with metastatic neuroendocrine tumours planned for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006 Jan 17:1–7 [Epub ahead of print]. DOI 10.1007/s00259-005-0006-1

  19. Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Quantitative PET studies in pretreated melanoma patients: a comparison of 6-(18F)-fluoro-L-dopa with 18F-FDG and 15O-water using compartment and noncompartment analysis. J Nucl Med 2001;42:248–256

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by DFG grants HA2901/3-1 and 3-2 from the Deutsche Forschungsgemeinschaft.

Author information

Authors and Affiliations

  1. Medical PET Group - Biological Imaging (E0601) Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    Antonia Dimitrakopoulou-Strauss, Sophia Koukouraki, Uwe Haberkorn & Ludwig G. Strauss

  2. Department of Medical Oncology, University of Crete, Herakleion, Greece

    Vassilios Georgoulias

  3. Department of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

    Michael Eisenhut

  4. Department of Pulmonology, Thoraxklinik Rohrbach, University of Heidelberg, Heidelberg, Germany

    Felix Herth

  5. Department of Nuclear Medicine, University of Crete, Herakleion, Greece

    Sophia Koukouraki

  6. Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Basel, Switzerland

    Helmut R. Mäcke

  7. Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany

    Uwe Haberkorn

Authors
  1. Antonia Dimitrakopoulou-Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vassilios Georgoulias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Eisenhut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felix Herth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sophia Koukouraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Helmut R. Mäcke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Uwe Haberkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ludwig G. Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonia Dimitrakopoulou-Strauss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dimitrakopoulou-Strauss, A., Georgoulias, V., Eisenhut, M. et al. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using68Ga-DOTATOC PET and comparison with18F-FDG PET. Eur J Nucl Med Mol Imaging 33, 823–830 (2006). https://doi.org/10.1007/s00259-005-0063-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-0063-5

Keywords

Search

Navigation